Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zinc Ion SCHEMBL3712583 | 0.86 | — | — | |
| SCHEMBL3710809 | 0.86 | — | — | |
| SCHEMBL3180572 | 0.86 | ALDH1A1 (0.33) | — | |
| Lithium Ion SCHEMBL387766 | 0.86 | — | — | |
| Lithium Ion SCHEMBL30157371 | 0.86 | ALDH1A1 (0.33) | — | |
| SCHEMBL7243361 | 0.86 | — | — | |
| Lithium Ion SCHEMBL8784828 | 0.80 | ALDH1A1 (0.30) | — | |
| Lithium Ion SCHEMBL11412267 | 0.80 | — | — | |
| SCHEMBL10509344 | 0.76 | — | — | |
| SCHEMBL10415229 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181966-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-7504508-B2 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| EP-1740547-A1 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2005-11-17 | — | — | US | disclosed |
| WO-2005100321-A1 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
| US-6313297-B1 | CATALYTIC ALKYLATION; BY-PRODUCT INHIBITION | AVENTIS RESEARCH & TECHNOLOGIES (DE) | 2001-11-06 | — | — | US | disclosed |
| EP-1047680-A2 | BASE-CATALYZED SYNTHESIS OF 1-ARYL-4-(ARYL ETHYL)PIPERAZINES FROM AROMATIC OLEFINS AND 1-ARYL PIPERAZINES | Aventis Research & Technologies GmbH & Co KG (DE) | 2000-11-02 | — | — | EP | disclosed |
| WO-1999036412-A2 | BASE-CATALYZED SYNTHESIS OF 1-ARYL-4-(ARYL ETHYL)PIPERAZINES FROM AROMATIC OLEFINS AND 1-ARYL PIPERAZINES | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO. KG (DE) | 1999-07-22 | — | — | WO | disclosed |